72 related articles for article (PubMed ID: 21205090)
41. Metabolic abnormalities induced by mitochondrial dysfunction in skeletal muscle of the renal carcinoma Eker (TSC2+/-) rat model.
Aizawa Y; Shirai T; Kobayashi T; Hino O; Tsujii Y; Inoue H; Kazami M; Tadokoro T; Suzuki T; Kobayashi K; Yamamoto Y
Biosci Biotechnol Biochem; 2016 Aug; 80(8):1513-9. PubMed ID: 27031579
[TBL] [Abstract][Full Text] [Related]
42. Serum level of expressed in renal carcinoma (ERC)/ mesothelin in rats with mesothelial proliferative lesions induced by multi-wall carbon nanotube (MWCNT).
Sakamoto Y; Dai N; Hagiwara Y; Satoh K; Ohashi N; Fukamachi K; Tsuda H; Hirose A; Nishimura T; Hino O; Ogata A
J Toxicol Sci; 2010 Apr; 35(2):265-70. PubMed ID: 20371980
[TBL] [Abstract][Full Text] [Related]
43. Distribution of Tsc2 protein in various normal rat tissues and renal tumours of Tsc2 mutant (Eker) rat detected by immunohistochemistry.
Fukuda T; Kobayashi T; Yasui H; Tsutsumi M; Konishi Y; Hino O
Virchows Arch; 1999 Apr; 434(4):341-50. PubMed ID: 10335945
[TBL] [Abstract][Full Text] [Related]
44. The Inhibitory Effects of Anti-ERC/Mesothelin Antibody 22A31 on Colorectal Adenocarcinoma Cells, within a Mouse Xenograft Model.
Taniguchi G; Kajino K; Momose S; Saeki H; Yue L; Ohtsuji N; Abe M; Shibuya T; Orimo A; Nagahara A; Watanabe S; Hino O
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565327
[TBL] [Abstract][Full Text] [Related]
45. Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.
Fukamachi K; Iigo M; Hagiwara Y; Shibata K; Futakuchi M; Alexander DB; Hino O; Suzui M; Tsuda H
PLoS One; 2014; 9(10):e111481. PubMed ID: 25347530
[TBL] [Abstract][Full Text] [Related]
46. The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma.
Saeki H; Hashizume A; Izumi H; Suzuki F; Ishi K; Nojima M; Maeda M; Hino O
Oncol Lett; 2012 Oct; 4(4):637-641. PubMed ID: 23205076
[TBL] [Abstract][Full Text] [Related]
47. Multistep renal carcinogenesis as gene expression disease in tumor suppressor TSC2 gene mutant model--genotype, phenotype and environment.
Hino O; Majima S; Kobayashi T; Honda S; Momose S; Kikuchi Y; Mitani H
Mutat Res; 2001 Jun; 477(1-2):155-64. PubMed ID: 11376696
[TBL] [Abstract][Full Text] [Related]
48. Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma.
Koyanagi AI; Kajino K; Nojiri S; Abe M; Kobayashi T; Sugitani Y; Yue L; Ohtsuji N; Arakawa A; Sato T; Takahashi K; Suzuki K; Orimo A; Yao T; Hino O
Juntendo Iji Zasshi; 2023; 69(2):124-136. PubMed ID: 38854453
[TBL] [Abstract][Full Text] [Related]
49. Heterozygous Tsc2 (Tsc2+/-) mouse model to study induced renal cancer in response to ionizing radiation at low doses.
M A S; Delma CR; Manickam K; Mohan S; Habib SL; Natarajan M
Carcinogenesis; 2019 Jul; 40(6):782-790. PubMed ID: 30508035
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic tumor marker of asbestos-related mesothelioma.
Hino O; Maeda M
Environ Health Prev Med; 2008 Mar; 13(2):71-4. PubMed ID: 19568884
[TBL] [Abstract][Full Text] [Related]
51. [Eetiological hypotheses of renal carcinoma onset].
Zhurkina OV
Urologiia; 2011; (6):108-11. PubMed ID: 22448494
[No Abstract] [Full Text] [Related]
52. ERC-the next 10 years.
Nowotny H
Science; 2017 Mar; 355(6329):997. PubMed ID: 28280155
[No Abstract] [Full Text] [Related]
53. The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis.
Fuji H; Miller G; Nishio T; Koyama Y; Lam K; Zhang V; Loomba R; Brenner D; Kisseleva T
Front Mol Biosci; 2021; 8():790032. PubMed ID: 34966784
[TBL] [Abstract][Full Text] [Related]
54. Role of mesothelin in carbon nanotube-induced carcinogenic transformation of human bronchial epithelial cells.
He X; Despeaux E; Stueckle TA; Chi A; Castranova V; Dinu CZ; Wang L; Rojanasakul Y
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L538-49. PubMed ID: 27422997
[TBL] [Abstract][Full Text] [Related]
55. Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer.
Zervos E; Agle S; Freistaedter AG; Jones GJ; Roper RL
J Exp Clin Cancer Res; 2016 Mar; 35():39. PubMed ID: 26931187
[TBL] [Abstract][Full Text] [Related]
56. Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice.
Zhang J; Bera TK; Liu W; Du X; Alewine C; Hassan R; Pastan I
PLoS One; 2014; 9(8):e104388. PubMed ID: 25118887
[TBL] [Abstract][Full Text] [Related]
57. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation.
Bharadwaj U; Marin-Muller C; Li M; Chen C; Yao Q
Carcinogenesis; 2011 Jul; 32(7):1013-24. PubMed ID: 21515913
[TBL] [Abstract][Full Text] [Related]
58. Deficiency of the Erc/mesothelin gene ameliorates renal carcinogenesis in Tsc2 knockout mice.
Zhang D; Kobayashi T; Kojima T; Kanenishi K; Hagiwara Y; Abe M; Okura H; Hamano Y; Sun G; Maeda M; Jishage K; Noda T; Hino O
Cancer Sci; 2011 Apr; 102(4):720-7. PubMed ID: 21205090
[TBL] [Abstract][Full Text] [Related]
59. siRNA-mediated Erc gene silencing suppresses tumor growth in Tsc2 mutant renal carcinoma model.
Imamura O; Okada H; Takashima Y; Zhang D; Kobayashi T; Hino O
Cancer Lett; 2008 Sep; 268(2):278-85. PubMed ID: 18490101
[TBL] [Abstract][Full Text] [Related]
60. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model.
Yamashita Y; Yokoyama M; Kobayashi E; Takai S; Hino O
Biochem Biophys Res Commun; 2000 Aug; 275(1):134-40. PubMed ID: 10944454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
